Skip to Content
Merck
CN

SML2941

Maribavir

≥98% (HPLC)

Synonym(s):

(2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 1263W94, Benzimidavir, VP-41263

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C15H19Cl2N3O4
CAS Number:
176161-24-3
Molecular Weight:
376.24
NACRES:
NA.77
UNSPSC Code:
12352200

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Maribavir, ≥98% (HPLC)

InChI

1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1

InChI key

KJFBVJALEQWJBS-XUXIUFHCSA-N

SMILES string

CC(NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@@H]3[C@@H](O)[C@@H](O)[C@H](CO)O3)C

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

Biochem/physiol Actions

Maribavir is an orally available antiviral agent under development for treatment and prevention of human cytomegalovirus (HCMV) infection. Maribavir is a potent and selective ATP-competitive inhibitor of HCMV protein kinase pUL97 that blocks viral replication.
potent and selective ATP-competitive inhibitor of HCMV protein kinase pUL97; orally available antiviral agent

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000119245
0000119246
0000110076

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Valentine Faure Bardon et al.
PloS one, 15(4), e0232140-e0232140 (2020-05-01)
Congenital cytomegalovirus infection can lead to severe sequelae. When fetal infection is confirmed, we hypothesize that fetal treatment could improve the outcome. Maternal oral administration of an effective drug crossing the placenta could allow fetal treatment. Letermovir (LMV) and Maribavir
Karen K Biron et al.
Antimicrobial agents and chemotherapy, 46(8), 2365-2372 (2002-07-18)
Benzimidazole nucleosides have been shown to be potent inhibitors of human cytomegalovirus (HCMV) replication in vitro. As part of the exploration of structure-activity relationships within this series, we synthesized the 2-isopropylamino derivative (3322W93) of 1H-beta-D-ribofuranoside-2-bromo-5,6-dichlorobenzimidazole (BDCRB) and the biologically unnatural
Mirjam Steingruber et al.
Microorganisms, 8(4) (2020-04-09)
Human cytomegalovirus (HCMV) expresses a variety of viral regulatory proteins that undergo close interaction with host factors including viral-cellular multiprotein complexes. The HCMV protein kinase pUL97 represents a viral cyclin-dependent kinase ortholog (vCDK) that determines the efficiency of HCMV replication

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service